A citation-based method for searching scientific literature

Keith S Hoek, Colin R Goding. Pigment Cell Melanoma Res 2010
Times Cited: 321







List of co-cited articles
1033 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


In vivo switching of human melanoma cells between proliferative and invasive states.
Keith S Hoek, Ossia M Eichhoff, Natalie C Schlegel, Udo Döbbeling, Nikita Kobert, Leo Schaerer, Silvio Hemmi, Reinhard Dummer. Cancer Res 2008
443
39

Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
Suzanne Carreira, Jane Goodall, Laurence Denat, Mercedes Rodriguez, Paolo Nuciforo, Keith S Hoek, Alessandro Testori, Lionel Larue, Colin R Goding. Genes Dev 2006
400
38

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Judith Müller, Oscar Krijgsman, Jennifer Tsoi, Lidia Robert, Willy Hugo, Chunying Song, Xiangju Kong, Patricia A Possik, Paulien D M Cornelissen-Steijger, Marnix H Geukes Foppen,[...]. Nat Commun 2014
353
37

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.
Annelien Verfaillie, Hana Imrichova, Zeynep Kalender Atak, Michael Dewaele, Florian Rambow, Gert Hulselmans, Valerie Christiaens, Dmitry Svetlichnyy, Flavie Luciani, Laura Van den Mooter,[...]. Nat Commun 2015
225
36

Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, Sara Aibar, Julia Femel, Michael Dewaele, Panagiotis Karras, Daniel Brown, Young Hwan Chang, Maria Debiec-Rychter,[...]. Cell 2018
241
36

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Itay Tirosh, Benjamin Izar, Sanjay M Prakadan, Marc H Wadsworth, Daniel Treacy, John J Trombetta, Asaf Rotem, Christopher Rodman, Christine Lian, George Murphy,[...]. Science 2016
34

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Keith S Hoek, Natalie C Schlegel, Patricia Brafford, Antje Sucker, Selma Ugurel, Rajiv Kumar, Barbara L Weber, Katherine L Nathanson, David J Phillips, Meenhard Herlyn,[...]. Pigment Cell Res 2006
363
34

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.
Jennifer Tsoi, Lidia Robert, Kim Paraiso, Carlos Galvan, Katherine M Sheu, Johnson Lay, Deborah J L Wong, Mohammad Atefi, Roksana Shirazi, Xiaoyan Wang,[...]. Cancer Cell 2018
265
29

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Paola Falletta, Luis Sanchez-Del-Campo, Jagat Chauhan, Maike Effern, Amy Kenyon, Christopher J Kershaw, Robert Siddaway, Richard Lisle, Rasmus Freter, Matthew J Daniels,[...]. Genes Dev 2017
136
27

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Levi A Garraway, Hans R Widlund, Mark A Rubin, Gad Getz, Aaron J Berger, Sridhar Ramaswamy, Rameen Beroukhim, Danny A Milner, Scott R Granter, Jinyan Du,[...]. Nature 2005
26

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
Jennifer Landsberg, Judith Kohlmeyer, Marcel Renn, Tobias Bald, Meri Rogava, Mira Cron, Martina Fatho, Volker Lennerz, Thomas Wölfel, Michael Hölzel,[...]. Nature 2012
358
24

Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities.
Florian Rambow, Jean-Christophe Marine, Colin R Goding. Genes Dev 2019
90
26

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
David J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, Jong Wook Kim, Zachary A Cooper, Adriano Piris, Dennie T Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq,[...]. Cancer Discov 2014
318
23

A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.
Julie Caramel, Eftychios Papadogeorgakis, Louise Hill, Gareth J Browne, Geoffrey Richard, Anne Wierinckx, Gerald Saldanha, Joy Osborne, Peter Hutchinson, Gina Tse,[...]. Cancer Cell 2013
325
22


Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.
Y Cheli, S Giuliano, T Botton, S Rocchi, V Hofman, P Hofman, P Bahadoran, C Bertolotto, R Ballotti. Oncogene 2011
156
19

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.
Alexander Roesch, Mizuho Fukunaga-Kalabis, Elizabeth C Schmidt, Susan E Zabierowski, Patricia A Brafford, Adina Vultur, Devraj Basu, Phyllis Gimotty, Thomas Vogt, Meenhard Herlyn. Cell 2010
807
19

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.
Stefanie Riesenberg, Angela Groetchen, Robert Siddaway, Tobias Bald, Julia Reinhardt, Denise Smorra, Judith Kohlmeyer, Marcel Renn, Bengt Phung, Pia Aymans,[...]. Nat Commun 2015
117
19

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.
Sydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, Eduardo A Torre, Benjamin Emert, Clemens Krepler, Marilda Beqiri, Katrin Sproesser, Patricia A Brafford, Min Xiao,[...]. Nature 2017
477
19

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.
Y Cheli, S Giuliano, N Fenouille, M Allegra, V Hofman, P Hofman, P Bahadoran, J-P Lacour, S Tartare-Deckert, C Bertolotto,[...]. Oncogene 2012
127
18

Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.
Jane Goodall, Suzanne Carreira, Laurence Denat, Dominique Kobi, Irwin Davidson, Paolo Nuciforo, Richard A Sturm, Lionel Larue, Colin R Goding. Cancer Res 2008
131
18

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry,[...]. Cell 2016
18

MITF-the first 25 years.
Colin R Goding, Heinz Arnheiter. Genes Dev 2019
119
18

Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.
Sophie Pinner, Peter Jordan, Kirsty Sharrock, Laura Bazley, Lucy Collinson, Richard Marais, Elise Bonvin, Colin Goding, Erik Sahai. Cancer Res 2009
149
17

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Willy Hugo, Hubing Shi, Lu Sun, Marco Piva, Chunying Song, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Kimberly B Dahlman, Douglas B Johnson,[...]. Cell 2015
365
16

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Julia Boshuizen, Louise A Koopman, Oscar Krijgsman, Aida Shahrabi, Elke Gresnigt- van den Heuvel, Maarten A Ligtenberg, David W Vredevoogd, Kristel Kemper, Thomas Kuilman, Ji-Ying Song,[...]. Nat Med 2018
112
16

Phenotype plasticity as enabler of melanoma progression and therapy resistance.
Imanol Arozarena, Claudia Wellbrock. Nat Rev Cancer 2019
126
16

MITF: master regulator of melanocyte development and melanoma oncogene.
Carmit Levy, Mehdi Khaled, David E Fisher. Trends Mol Med 2006
718
15

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
Michael P O'Connell, Katie Marchbank, Marie R Webster, Alexander A Valiga, Amanpreet Kaur, Adina Vultur, Ling Li, Meenhard Herlyn, Jessie Villanueva, Qin Liu,[...]. Cancer Discov 2013
158
14

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
Rizwan Haq, Jonathan Shoag, Pedro Andreu-Perez, Satoru Yokoyama, Hannah Edelman, Glenn C Rowe, Dennie T Frederick, Aeron D Hurley, Abhinav Nellore, Andrew L Kung,[...]. Cancer Cell 2013
548
14

Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.
Kristel Kemper, Pauline L de Goeje, Daniel S Peeper, Renée van Amerongen. Cancer Res 2014
130
14

A landscape of driver mutations in melanoma.
Eran Hodis, Ian R Watson, Gregory V Kryukov, Stefan T Arold, Marcin Imielinski, Jean-Philippe Theurillat, Elizabeth Nickerson, Daniel Auclair, Liren Li, Chelsea Place,[...]. Cell 2012
13

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
13

Directed phenotype switching as an effective antimelanoma strategy.
Magalí Sáez-Ayala, María F Montenegro, Luis Sánchez-Del-Campo, María Piedad Fernández-Pérez, Soledad Chazarra, Rasmus Freter, Mark Middleton, Antonio Piñero-Madrona, Juan Cabezas-Herrera, Colin R Goding,[...]. Cancer Cell 2013
85
15


Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF.
Erez Feige, Satoru Yokoyama, Carmit Levy, Mehdi Khaled, Vivien Igras, Richard J Lin, Stephen Lee, Hans R Widlund, Scott R Granter, Andrew L Kung,[...]. Proc Natl Acad Sci U S A 2011
86
15

STAR: ultrafast universal RNA-seq aligner.
Alexander Dobin, Carrie A Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali Jha, Philippe Batut, Mark Chaisson, Thomas R Gingeras. Bioinformatics 2013
13


Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression.
Suzanne Carreira, Jane Goodall, Isil Aksan, S Anna La Rocca, Marie-Dominique Galibert, Laurence Denat, Lionel Larue, Colin R Goding. Nature 2005
279
12

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
Mohammad Fallahi-Sichani, Verena Becker, Benjamin Izar, Gregory J Baker, Jia-Ren Lin, Sarah A Boswell, Parin Shah, Asaf Rotem, Levi A Garraway, Peter K Sorger. Mol Syst Biol 2017
124
12

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Michael P Smith, Holly Brunton, Emily J Rowling, Jennifer Ferguson, Imanol Arozarena, Zsofia Miskolczi, Jessica L Lee, Maria R Girotti, Richard Marais, Mitchell P Levesque,[...]. Cancer Cell 2016
140
12

Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth.
Jennifer Ferguson, Michael Smith, Isabel Zudaire, Claudia Wellbrock, Imanol Arozarena. Oncotarget 2017
31
38

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
Geoffrey Richard, Stéphane Dalle, Marie-Ambre Monet, Maud Ligier, Amélie Boespflug, Roxane M Pommier, Arnaud de la Fouchardière, Marie Perier-Muzet, Lauriane Depaepe, Romain Barnault,[...]. EMBO Mol Med 2016
75
16

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.
Arnav Mehta, Yeon Joo Kim, Lidia Robert, Jennifer Tsoi, Begoña Comin-Anduix, Beata Berent-Maoz, Alistair J Cochran, James S Economou, Paul C Tumeh, Cristina Puig-Saus,[...]. Cancer Discov 2018
76
15

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
Cory M Johannessen, Laura A Johnson, Federica Piccioni, Aisha Townes, Dennie T Frederick, Melanie K Donahue, Rajiv Narayan, Keith T Flaherty, Jennifer A Wargo, David E Root,[...]. Nature 2013
324
11

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.
G Denecker, N Vandamme, O Akay, D Koludrovic, J Taminau, K Lemeire, A Gheldof, B De Craene, M Van Gele, L Brochez,[...]. Cell Death Differ 2014
119
11

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Chong Sun, Liqin Wang, Sidong Huang, Guus J J E Heynen, Anirudh Prahallad, Caroline Robert, John Haanen, Christian Blank, Jelle Wesseling, Stefan M Willems,[...]. Nature 2014
526
11

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF.
Jinyan Du, Hans R Widlund, Martin A Horstmann, Sridhar Ramaswamy, Ken Ross, Wade E Huber, Emi K Nishimura, Todd R Golub, David E Fisher. Cancer Cell 2004
287
11

Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching.
Daniel S Widmer, Keith S Hoek, Phil F Cheng, Ossia M Eichhoff, Thomas Biedermann, Marieke I G Raaijmakers, Silvio Hemmi, Reinhard Dummer, Mitchell P Levesque. J Invest Dermatol 2013
98
11

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
Corine Bertolotto, Fabienne Lesueur, Sandy Giuliano, Thomas Strub, Mahaut de Lichy, Karine Bille, Philippe Dessen, Benoit d'Hayer, Hamida Mohamdi, Audrey Remenieras,[...]. Nature 2011
331
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.